Search hospitals > Ontario > BARRIE
Royal Victoria Regional Health Centre
Claim this profileBARRIE, Ontario L4M 6M2
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
106 reported clinical trials
8 medical researchers
Summary
Royal Victoria Regional Health Centre is a medical facility located in BARRIE, Ontario. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Royal Victoria Regional Health Centre is involved with conducting 106 clinical trials across 110 conditions. There are 8 research doctors associated with this hospital, such as Adam Gladwish, MD, Christiaan S. Stevens, Giulio Didiodato, MD, and Jason S. Yu.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Cancer
Global LeaderStage III
Stage IV
BRCA1 positive
Top PIs
Adam Gladwish, MDRoyal Victoria Regional Health Centre4 years of reported clinical research
Studies Prostate Cancer
Studies Endometrial Cancer
3 reported clinical trials
6 drugs studied
Christiaan S. StevensRoyal Victoria Regional Health Centre5 years of reported clinical research
Studies Breast Cancer
2 reported clinical trials
5 drugs studied
Giulio Didiodato, MDRoyal Victoria Regional Health Centre4 years of reported clinical research
Studies Opioid Use Disorder
Studies Coronavirus
2 reported clinical trials
10 drugs studied
Jason S. YuRoyal Victoria Regional Health Centre5 years of reported clinical research
Studies Endometrioid Carcinoma
Studies Cancer
1 reported clinical trial
3 drugs studied
Clinical Trials running at Royal Victoria Regional Health Centre
Breast Cancer
Melanoma
Skin Cancer
Non-Small Cell Lung Cancer
Kidney Tumors
Prostate Cancer
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma
Cutaneous Melanoma
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Giredestrant vs. Fulvestrant
for Advanced Breast Cancer
This trial is testing two drug combinations to treat a specific type of advanced breast cancer that no longer responds to standard hormone treatments. The goal is to see which combination works better by stopping the cancer cells from growing.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Royal Victoria Regional Health Centre?
Royal Victoria Regional Health Centre is a medical facility located in BARRIE, Ontario. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Royal Victoria Regional Health Centre is involved with conducting 106 clinical trials across 110 conditions. There are 8 research doctors associated with this hospital, such as Adam Gladwish, MD, Christiaan S. Stevens, Giulio Didiodato, MD, and Jason S. Yu.